Prothrombin Complex Concentrate (PCC) Kcentra™ has been approved for urgent reversal of major bleeding in patients taking vitamin K antagonists (e.g. warfarin).
It contains factors 2,7,9 and 10, and antithrombotic Proteins C and S.
Both fatal and non-fatal arterial and venous thromboembolic complications have occurred with Kcentra™. Thrombotic events occurred more frequently in the PCC group compared to plasma, although the differences were not statistically significant.
Volume overload occurred less frequently in the PCC group, as there is a smaller volume administered with PCC compared to that of plasma.
Percentage of INR ≤ 1.3 at 30 minutes was 62% in the PCC group and 9.6% in the plasma group.
Approval of Kcentra™ may open the door for studying treatment of the bleeding patient on newer oral anticoagulants.
